Cargando…

Progress in Biological Therapies for Adult-Onset Still’s Disease

Adult-onset Still’s disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting form...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galozzi, Paola, Bindoli, Sara, Doria, Andrea, Sfriso, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038152/ https://www.ncbi.nlm.nih.gov/pubmed/35481241 http://dx.doi.org/10.2147/BTT.S290329

Ejemplares similares

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

(18)F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Magnetic Resonance for Diagnosing Adult-Onset Still's Disease
por: Bindoli, Sara, et al.
Publicado: (2020)

IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome
por: Baggio, Chiara, et al.
Publicado: (2023)

Autoinflammatory Features in Gouty Arthritis
por: Galozzi, Paola, et al.
Publicado: (2021)

Autoinflammatory Mechanisms in Crystal-Induced Arthritis
por: Oliviero, Francesca, et al.
Publicado: (2020)

Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
por: Bindoli, Sara, et al.
Publicado: (2023)

Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study
por: Bindoli, Sara, et al.
Publicado: (2019)

A Pro-Inflammatory Signature Constitutively Activated in Monogenic Autoinflammatory Diseases
por: Galozzi, Paola, et al.
Publicado: (2022)

Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease
por: Caso, Francesco, et al.
Publicado: (2015)

Current and emerging biological therapy in adult-onset Still’s disease
por: Ma, Yuning, et al.
Publicado: (2021)

Clinical Overlapping in Autoinflammatory Diseases: The Role of Gene Duplication
por: Galozzi, Paola, et al.
Publicado: (2017)

Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review
por: Zhou, Sha, et al.
Publicado: (2018)

Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
por: Colafrancesco, Serena, et al.
Publicado: (2017)

Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout
por: Scanu, Anna, et al.
Publicado: (2022)

Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies
por: Mavragani, Clio P., et al.
Publicado: (2012)

Elderly-onset adult Still’s disease
por: Mzabi, Anis, et al.
Publicado: (2021)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
por: Vitale, Antonio, et al.
Publicado: (2019)

Adult-Onset Still’s Disease
por: Mitrovic, Stéphane, et al.
Publicado: (2019)

Adult-Onset Still’s Disease
por: Efthimiou, Petros, et al.
Publicado: (2018)

Treatment of adult-onset Still’s disease: a review
por: Jamilloux, Yvan, et al.
Publicado: (2014)

Mechanisms, biomarkers and targets for adult-onset Still’s disease
por: Feist, Eugen, et al.
Publicado: (2018)

Life-threatening complications of adult-onset Still’s disease
por: Efthimiou, Petros, et al.
Publicado: (2014)

Adult Onset Still's Disease and Autoinflammation
por: Efthimiou, Petros, et al.
Publicado: (2012)

Myocarditis in Adult-Onset Still Disease
por: Gerfaud-Valentin, Mathieu, et al.
Publicado: (2014)

Refractory Adult Onset Still’s Disease
por: Sulaiman, Wahinuddin, et al.
Publicado: (2017)

Strategy and Challenges of Paraclinical Examinations in Adult-Onset Still’s Disease
por: Poursac, Nicolas, et al.
Publicado: (2022)

Adult-onset Still’s disease: current challenges and future prospects
por: Siddiqui, Mariam, et al.
Publicado: (2016)

Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach
por: Tomaras, Stylianos, et al.
Publicado: (2021)

Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
por: Vitale, Antonio, et al.
Publicado: (2020)

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
por: Colafrancesco, Serena, et al.
Publicado: (2019)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Correction to: Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
por: Colafrancesco, Serena, et al.
Publicado: (2020)

Anti-Interleukin-1 Agents in Adult Onset Still's Disease
por: Giampietro, Cecilia, et al.
Publicado: (2012)

Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment
por: Macovei, Luana Andreea, et al.
Publicado: (2022)

Adult onset Still's disease: Role of scintigraphy
por: Nilegaonkar, Sujit, et al.
Publicado: (2012)

Adult onset Still’s disease with dermatopathic lymphadenopathy
por: Qureshi, Ahmad Z., et al.
Publicado: (2016)

Delay in the Diagnosis of Adult-Onset Still’s Disease
por: Pak, Stella, et al.
Publicado: (2017)

Flagellate Rash in Adult-onset Still's Disease
por: Patidar, Abhilasha, et al.
Publicado: (2020)

Atypical Presentation of Adult-Onset Still’s Disease
por: Sobhrakhshankhah, Elham, et al.
Publicado: (2023)

Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy
por: Vercruysse, François, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r77gh7ebhufa9jn81f9mql0rpl